Filing Summary: Cerulean Pharma Inc. — Q1 2015
Entity note: The supplied filing is Cerulean Pharma Inc.’s Form 10-Q, not a filing identified as Dare Bioscience, Inc. It covers the quarter ended March 31, 2015; the financial statements are unaudited.
Business context and reporting period
Cerulean was a clinical-stage oncology company developing nanoparticle-drug conjugates through its Dynamic Tumor Targeting platform. Its lead candidate, CRLX101, was in Phase 2 development; CRLX301 was in an ongoing Phase 1 trial. The company reported no product revenue and said commercialization, if achieved, was several years away.
Financial results and liquidity
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | $0 | $47,000 |
| Research and development expense | $5.021 million | $1.495 million |
| General and administrative expense | $2.681 million | $1.510 million |
| Operating loss | $7.702 million | $2.958 million |
| Net loss | $8.428 million | $2.914 million |
| Net loss per share | $0.41 | $3.70 |
| Cash used in operations | $7.941 million | $3.666 million |
No meaningful operating margin can be calculated because revenue was nil in Q1 2015. The larger net loss reflected increased development and corporate costs, as well as interest and financing-related expense. Reported loss per share is not directly comparable year over year: weighted-average shares rose from 786,986 to 20.35 million, following the 2014 IPO and conversion of securities.
At March 31, 2015, cash and cash equivalents were $56.316 million, versus $51.174 million at year-end 2014. Total current assets were $58.582 million and current liabilities were $5.289 million. The balance sheet reported loan payable of $14.412 million, including $836,000 current and $13.576 million long-term; non-current accrued interest was $108,000. Accumulated deficit was $130.209 million. Cash increased by $5.142 million during the quarter, principally because $13.112 million of financing cash flow exceeded operating and investing outflows.
On April 10, 2015, after quarter-end, Cerulean completed an offering of 6.716 million shares at $6.00 per share, for approximately $40.3 million gross proceeds before expenses. Management said cash at March 31 together with offering proceeds was expected to fund operations, debt service, and capital expenditures into 2017, subject to assumptions that could prove inaccurate.
Material changes and developments
- R&D expense increased $3.526 million year over year, primarily due to CRLX101 trial activity; CRLX301 spending also rose with its Phase 1 trial.
- G&A expense rose 78%, reflecting company growth, public-company costs, and increased personnel and professional fees.
- In January 2015, Cerulean borrowed $15 million under a new Hercules term loan and used part of the proceeds to repay its Lighthouse loan, which had approximately $3.6 million outstanding. The Hercules facility permits additional borrowing subject to clinical and financing conditions.
- Management reported that an investigator-sponsored Phase 1b/2 CRLX101-plus-Avastin trial in relapsed renal cell carcinoma met its stated primary endpoint: at least 50% of patients achieved four months of progression-free survival. Further data were expected at an oncology meeting in June 2015. The filing cautions that investigator-sponsored studies were ongoing and results were preliminary.
- The company signed an agreement for a Phase 1b CRLX101-plus-weekly-paclitaxel trial in relapsed ovarian cancer and expected first-patient enrollment in Q2 2015.
- On March 20, 2015, Christopher D.T. Guiffre became president and CEO. A post-quarter April 27 notice of FDA fast-track designation for CRLX101 in metastatic RCC is described in the filing’s risk-factor discussion.
Outlook, risks, and unusual items
Cerulean expected significant and increasing operating losses as it advanced CRLX101, CRLX301, and earlier-stage programs. It anticipated needing additional capital; equity financing could dilute shareholders, while debt or partnerships could impose restrictions or require relinquishing rights. The Hercules loan bears a floating rate with a stated floor of 7.30%, is secured by substantially all assets other than intellectual property, includes an intellectual-property negative pledge, and matures July 1, 2018. Further tranches depend on specified clinical and financing milestones.
Key risks include clinical-trial failure or enrollment delays, unproven technology, regulatory uncertainty, reliance on third-party researchers and manufacturers, manufacturing and supply constraints, competition, and dependence on licensed intellectual property. The filing also describes Calando’s bankruptcy and potential effects on licensed rights. It reports a prior CRLX101 Phase 2 NSCLC trial that failed its overall-survival primary endpoint.
The filing contains differing descriptions of the Hercules final payment: the loan note states 6.70% of aggregate original principal advanced, while the MD&A contractual-obligations section states 6.3% of the original $15 million principal. This should be checked against the loan agreement. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Separately, on May 1, 2015, Cerulean gave MIT notice terminating a license agreement, effective November 1, 2015 or sooner by agreement. The filing states that the licensed technology was not used by its platform or product candidates and that termination was not expected to affect them.
Important facts for investors to verify
- Confirm the issuer: this filing names Cerulean Pharma Inc., not Dare Bioscience, Inc.
- Review the Hercules agreement for the final-payment percentage, outstanding principal and accrued interest, covenants, collateral, and conditions on additional tranches.
- Verify net proceeds and share dilution from the April 2015 offering, and whether the stated runway into 2017 remained supportable under actual spending and trial plans.
- Assess the full clinical data behind the reported renal-cell-carcinoma endpoint and monitor enrollment and outcomes in company-sponsored trials.
- Evaluate the status and potential impact of Calando’s bankruptcy on Cerulean’s licensed intellectual property rights.